Jump to content

Doron Levy

Add links
From Wikipedia, the free encyclopedia
Doron Levy
Occupation(s)Mathematician, scientist, magician, and academic
Academic background
EducationB.Sc. in Mathematics and Physics
M.Sc. in Applied Mathematics
Ph.D. in Applied Mathematics
Alma materTel Aviv University
ThesisTopics in Approximate Methods for Non-Linear Partial Differential Equations (1997)
Doctoral advisorEitan Tadmor
Academic work
InstitutionsÉcole normale supérieure (Paris)
Paris 6 University (Sorbonne University)
University of California, Berkeley
Lawrence Berkeley National Laboratory
Stanford University
University of Maryland, College Park

Doron Levy is a mathematician, scientist, magician, and academic. He is a Professor and chair at the Department of Mathematics at the University of Maryland, College Park.[1] He is also the Director of the Brin Mathematics Research Center.[2]

Levy's research encompasses the field of numerical analysis, applied nonlinear partial differential equations, and biology and medical applications, particularly focusing on analyzing cancer dynamics, immunology, and cell motility. He has written more than 100 peer-reviewed articles. He is the recipient of the National Science Foundation Career Award.[3]

Levy is a Fellow of the John Simon Guggenheim Memorial Foundation[4] He is an Editorial Board Member of the Bulletin of Mathematical Biology,[5] Discrete and Continuous Dynamics Systems Series B, Le Matematiche,[6] Acta Applicandae Mathematicae,[7] Frontiers in Systems Biology, Cancer Research,[8] Applied Mathematics Modelling,[9] PLoS One,[10] and Differential Equations and Dynamical Systems.[11] He is the Editor-in-Chief at ImmunoInformatics.[1]

Education

[edit]

Levy earned his Baccalaureate degree in Mathematics and Physics in 1991 and completed a master's degree in Applied Mathematics in 1994 from Tel Aviv University. His Master's thesis was titled "From Semi-Discrete to Fully-Discrete: The Stability of Runge-Kutta Schemes by the Energy Method".[12] In 1997, he received a Ph.D. in Applied Mathematics under the guidance of Eitan Tadmor, with a thesis on "Topics in Approximate Methods for Non-Linear Partial Differential Equations." Afterward, he held several post-doctorate fellowships at Laboratoire d'Analyse Numerique (University of Paris 6), École normale supérieure (Paris), University of California, Berkeley, and the Lawrence Berkeley National Laboratory.[1]

Career

[edit]

Following his post-doctoral fellowship at Berkeley in 2000, Levy joined the Department of Mathematics at Stanford University as an assistant professor. In 2007, he was appointed as associate professor of mathematics and a member of the Center for Scientific Computation and Mathematical Modeling at the University of Maryland, College Park. In 2014, he became a Pauli Fellow at the Wolfgang Pauli Institute of the University of Vienna in Austria.[13] Since 2011, he has been a professor at the Department of Mathematics & Center for Scientific Computation and Mathematical Modeling of the University of Maryland, College Park.[14]

Levy served as a Member of the Board of Governors of the Institute for Mathematics and Its Applications (IMA) at the University of Minnesota in 2018 for one year, and a Member of the Board of Directors of the Society for Mathematical Biology from 2018 to 2022. Since 2022, he has been serving as the Founding Director of the Brin Mathematics Research Center at the University of Maryland, College Park.[2]

As of 2020, Levy has been a chair at the Department of Mathematics and the Director of the Center for Scientific Computation and Mathematical Modeling of the University of Maryland, College Park.[1]

Research

[edit]

Levy's research is focused on mathematical equations and biomedical applications of mathematics with a particular interest in cancer dynamics, drug resistance, drug delivery, immunology, imaging, and cell motility.

Numerical analysis

[edit]

During his early research career, Levy worked on developing and analyzing high-order numerical methods for approximating solutions to hyperbolic conservation law and related equations. He developed novel methods for approximating solutions to nonlinear partial differential equations including Euler equations, Navier-Stokes equations, Hamilton-Jacobi equations, nonlinear dispersive equations. Some of the approximation methods he developed used Weighted Essentially Non-Oscillatory (WENO) schemes.[15] He developed a third-order central scheme for approximating solutions of multidimensional hyperbolic conservation laws[16] and 2D conservation laws using compact central WENO reconstructions.[17] In a series of works with Steve Bryson, he proposed new high-order central schemes[18] for approximating solutions of multidimensional Hamilton-Jacobi equations.[19][20]

Cancer dynamics and the immune system

[edit]

Levy contributed to cancer dynamics by formulating a set of computational and mathematical tools designed for specific types of cancer.[21] He discussed the need for mathematical models to understand the complexity of breast and ovarian cancers[22] and proposed a model to explain the failure of transvaginal ultrasound-based screening in detecting low-volume high-grade serous ovarian cancer.[23] In a collaborative study, he investigated the effects of regulatory T cell switching the immune response and identified a biologically testable range for the switching parameter.[24] Furthermore, he presented mathematical models for studying cancer cell growth dynamics[25] in response to antimitotic drug treatment in vitro,[26] to understand the immunogenic effects of LSD1 inhibition on tumor growth and T cell dynamics,[27] and for the interaction between immune response and cancer cells in chronic myelogenous leukemia and analyzes the stability of steady states.[28]

Levy analyzed cancer's immune response mechanisms, particularly in chronic myeloid leukemia, providing insights into the role of the immune response and drug therapy in controlling the disease.[29] He also demonstrated that the autologous immune system may play a role in the BCR-ABL transcript variations observed in chronic phase chronic myelogenous leukemia patients on imatinib therapy.[30] Considering the problem of drug resistance in cancer[31] he suggested a simple compartmental system of ordinary differential equations to model it[32] and stated that drug resistance depends on the turnover rate of cancer cells.[33] Additionally, he extended a model of drug resistance in solid tumors to explore the dynamics of resistance levels and the emergence of heterogeneous tumors in response to chemotherapy.[34][35] Conducting a study on cervical cancer, he investigated the efficacy of combination immunotherapy using engineered T cells and IL-2.[36] Moreover, he assessed the influence of cell density,[37] intratumoral heterogeneity,[38] and mutations in multidrug resistance,[39] considering the continuum model as the most suitable approach for modeling resistance heterogeneity in metastasis.[40][41] In collaboration with Heyrim Cho, he also investigated the impact of competition between cancer cells and healthy cells on optimal drug delivery and indicated that in scenarios with moderate competition, combination therapies are more effective, whereas in highly competitive situations, targeted drugs prove to be more effective.[42]

Personal life

[edit]

Levy is a magician member of the Academy of Magical Arts in Hollywood (Magic Castle)[43] and a member of the Order of Merlin of the International Brotherhood of Magicians (I.B.M.).[44] Throughout his academic career, he has highlighted the connection between performing arts and the academic world.

Awards and honors

[edit]

Selected articles

[edit]
  • Levy, D., & Tadmor, E. (1998). From semidiscrete to fully discrete: Stability of Runge—Kutta schemes by the energy method. SIAM review, 40(1), 40–73.
  • Kim, P. S., Lee, P. P., & Levy, D. (2008). Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS computational biology, 4(6), e1000095.
  • Tomasetti, C., & Levy, D. (2010). Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proceedings of the National Academy of Sciences, 107(39), 16766–16771.
  • Lavi, O., Greene, J. M., Levy, D., & Gottesman, M. M. (2013). The role of cell density and intratumoral heterogeneity in multidrug resistance. Cancer research, 73(24), 7168–7175.
  • Cho, H., & Levy, D. (2018). Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth. Journal of theoretical biology, 436, 120–134.

References

[edit]
  1. ^ a b c d "Dr. Doron Levy, PhD – Editorial Board – ImmunoInformatics – Journal – Elsevier". www.journals.elsevier.com.
  2. ^ a b "MRC Director". Brin MRC.
  3. ^ a b "NSF Award Search: Award # 0820817 – Career: Partial Differential Equation-based Image Processing with Applications to Radiation Oncology". www.nsf.gov.
  4. ^ a b "Doron Levy". John Simon Guggenheim Memorial Foundation...
  5. ^ "Bulletin of Mathematical Biology – Editors".
  6. ^ "Editorial Team – Le Matematiche".
  7. ^ "Editors – Acta Applicandae Mathematicae".
  8. ^ "Editors – Cancer Research – American Association for Cancer Research".
  9. ^ "Editorial board – Applied Mathematical Modelling – ScienceDirect.com by Elsevier".
  10. ^ "Editorial Board – PLOS ONE".
  11. ^ "Differential Equations and Dynamical Systems – Editors".
  12. ^ Levy, Doron; Tadmor, Eitan (January 11, 1998). "From Semidiscrete to Fully Discrete: Stability of Runge—Kutta Schemes by The Energy Method". SIAM Review. 40 (1): 40–73. Bibcode:1998SIAMR..40...40L. doi:10.1137/S0036144597316255. hdl:1903/8644 – via CrossRef.
  13. ^ "Wolfgang Pauli Institute (WPI)". www.wpi.ac.at.
  14. ^ "Department of Mathematics – Levy, Doron". www-math.umd.edu.
  15. ^ Levy, Doron; Puppo, Gabriella; Russo, Giovanni (May 1, 2000). "On the behavior of the total variation in CWENO methods for conservation laws". Applied Numerical Mathematics. 33 (1): 407–414. doi:10.1016/S0168-9274(99)00107-5 – via ScienceDirect.
  16. ^ Levy, Doron; Puppo, Gabriella; Russo, Giovanni (January 11, 2000). "Compact Central WENO Schemes for Multidimensional Conservation Laws". SIAM Journal on Scientific Computing. 22 (2): 656–672. arXiv:math/9911089. Bibcode:2000SJSC...22..656L. doi:10.1137/S1064827599359461. S2CID 12442855 – via CrossRef.
  17. ^ Levy, Doron; Puppo, Gabriella; Russo, Giovanni (May 1, 2000). "A third order central WENO scheme for 2D conservation laws". Applied Numerical Mathematics. 33 (1): 415–421. doi:10.1016/S0168-9274(99)00108-7 – via ScienceDirect.
  18. ^ Bryson, S.; Levy, D. (August 11, 2003). "High-order central WENO schemes for 1D Hamilton-Jacobi equations". In Brezzi, Franco; Buffa, Annalisa; Corsaro, Stefania; Murli, Almerico (eds.). Numerical Mathematics and Advanced Applications. Springer Milan. pp. 45–54. doi:10.1007/978-88-470-2089-4_4. hdl:2060/20020059594. ISBN 978-88-470-2167-9 – via Springer Link.
  19. ^ Bryson, Steve; Levy, Doron (January 11, 2003). "High-Order Central WENO Schemes for Multidimensional Hamilton-Jacobi Equations". SIAM Journal on Numerical Analysis. 41 (4): 1339–1369. doi:10.1137/S0036142902408404. hdl:2060/20020066776. S2CID 5842936 – via CrossRef.
  20. ^ Levy, Doron; Nayak, Suhas; Shu, Chi-Wang; Zhang, Yong-Tao (January 11, 2006). "Central WENO Schemes for Hamilton–Jacobi Equations on Triangular Meshes". SIAM Journal on Scientific Computing. 28 (6): 2229–2247. Bibcode:2006SJSC...28.2229L. doi:10.1137/040612002 – via CrossRef.
  21. ^ Peet, M. M.; Kim, P. S.; Niculescu, S.-I.; Levy, D. (January 11, 2009). "New Computational Tools for Modeling Chronic Myelogenous Leukemia". Mathematical Modelling of Natural Phenomena. 4 (2): 119–139. doi:10.1051/mmnp/20094206.
  22. ^ Botesteanu, Dana-Adriana; Lipkowitz, Stanley; Lee, Jung-Min; Levy, Doron (July 11, 2016). "Mathematical models of breast and ovarian cancers". WIREs Systems Biology and Medicine. 8 (4): 337–362. doi:10.1002/wsbm.1343. PMC 4911289. PMID 27259061.
  23. ^ Botesteanu, Dana-Adriana; Lee, Jung-Min; Levy, Doron (June 3, 2016). "Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection". PLOS ONE. 11 (6): e0156661. Bibcode:2016PLoSO..1156661B. doi:10.1371/journal.pone.0156661. PMC 4892570. PMID 27257824.
  24. ^ Wilson, Shelby; Levy, Doron (October 1, 2013). "Functional Switching and Stability of Regulatory T Cells". Bulletin of Mathematical Biology. 75 (10): 1891–1911. doi:10.1007/s11538-013-9875-9. PMID 23917986. S2CID 255314821 – via Springer Link.
  25. ^ Greene, James M.; Levy, Doron; Fung, King Leung; Souza, Paloma S.; Gottesman, Michael M.; Lavi, Orit (February 21, 2015). "Modeling intrinsic heterogeneity and growth of cancer cells". Journal of Theoretical Biology. 367: 262–277. doi:10.1016/j.jtbi.2014.11.017. PMC 4308514. PMID 25457229.
  26. ^ Lorz, Alexander; Botesteanu, Dana-Adriana; Levy, Doron (August 11, 2017). "Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment". Frontiers in Oncology. 7: 189. doi:10.3389/fonc.2017.00189. PMC 5582072. PMID 28913178.
  27. ^ Milzman, Jesse; Sheng, Wanqiang; Levy, Doron (January 12, 2021). "Modeling LSD1-Mediated Tumor Stagnation". Bulletin of Mathematical Biology. 83 (2): 15. doi:10.1007/s11538-020-00842-8. PMID 33433736. S2CID 231586558 – via Springer Link.
  28. ^ Besse, Apollos; Clapp, Geoffrey D.; Bernard, Samuel; Nicolini, Franck E.; Levy, Doron; Lepoutre, Thomas (May 1, 2018). "Stability Analysis of a Model of Interaction Between the Immune System and Cancer Cells in Chronic Myelogenous Leukemia". Bulletin of Mathematical Biology. 80 (5): 1084–1110. doi:10.1007/s11538-017-0272-7. PMID 28536994. S2CID 4036621 – via Springer Link.
  29. ^ "The role of the autologous immune response in chronic myelogenous leukemia".
  30. ^ Clapp, Geoffrey D.; Lepoutre, Thomas; Nicolini, Franck E.; Levy, Doron (May 3, 2016). "BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system". OncoImmunology. 5 (5): e1122159. doi:10.1080/2162402X.2015.1122159. PMC 4910749. PMID 27467931.
  31. ^ Lavi, Orit; Gottesman, Michael M.; Levy, Doron (February 1, 2012). "The dynamics of drug resistance: A mathematical perspective". Drug Resistance Updates. 15 (1): 90–97. doi:10.1016/j.drup.2012.01.003. PMC 3348255. PMID 22387162.
  32. ^ Tomasetti, C.; Levy, D. (2010). "An Elementary Approach to Modeling Drug Resistance in Cancer". Mathematical Biosciences and Engineering. 7 (4): 905–918. doi:10.3934/mbe.2010.7.905. PMC 3877932. PMID 21077714.
  33. ^ Tomasetti, C.; Levy, D. (August 11, 2010). "Drug Resistance always Depends on the Turnover Rate". In Herold, Keith E.; Vossoughi, Jafar; Bentley, William E. (eds.). 26th Southern Biomedical Engineering Conference SBEC 2010, April 30 - May 2, 2010, College Park, Maryland, USA. IFMBE Proceedings. Vol. 32. Springer. pp. 552–555. doi:10.1007/978-3-642-14998-6_141. ISBN 978-3-642-14997-9 – via Springer Link.
  34. ^ Cho, Heyrim; Levy, Doron (December 1, 2017). "Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy". Bulletin of Mathematical Biology. 79 (12): 2986–3012. doi:10.1007/s11538-017-0359-1. PMID 29022203. S2CID 41563051 – via Springer Link.
  35. ^ Becker, Matthew; Levy, Doron (October 1, 2017). "Modeling the Transfer of Drug Resistance in Solid Tumors". Bulletin of Mathematical Biology. 79 (10): 2394–2412. doi:10.1007/s11538-017-0334-x. hdl:1903/20883. PMID 28852953. S2CID 255318869 – via Springer Link.
  36. ^ Cho, Heyrim; Wang, Zuping; Levy, Doron (November 21, 2020). "Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer". Journal of Theoretical Biology. 505: 110403. arXiv:2001.10573. Bibcode:2020JThBi.50510403C. doi:10.1016/j.jtbi.2020.110403. PMID 32693004. S2CID 210942624 – via ScienceDirect.
  37. ^ "Mathematical Modeling Reveals That Changes to Local Cell Density Dynamically Modulate Baseline Variations in Cell Growth and Drug Response".
  38. ^ "The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance".
  39. ^ Greene, James; Lavi, Orit; Gottesman, Michael M.; Levy, Doron (March 1, 2014). "The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors". Bulletin of Mathematical Biology. 76 (3): 627–653. doi:10.1007/s11538-014-9936-8. PMC 4794109. PMID 24553772 – via Springer Link.
  40. ^ "Simplifying the complexity of resistance heterogeneity in metastasis: Trends in Molecular Medicine".
  41. ^ Cho, Heyrim; Levy, Doron (December 1, 2018). "Modeling continuous levels of resistance to multidrug therapy in cancer". Applied Mathematical Modelling. 64: 733–751. arXiv:1806.07557. doi:10.1016/j.apm.2018.07.025. S2CID 49322143 – via ScienceDirect.
  42. ^ Cho, Heyrim; Levy, Doron (August 11, 2020). "The impact of competition between cancer cells and healthy cells on optimal drug delivery". Mathematical Modelling of Natural Phenomena. 15: 42. arXiv:1806.07477. doi:10.1051/mmnp/2019043 – via www.mmnp-journal.org.
  43. ^ "Guggenheim Fellow - Doron Levy".
  44. ^ Samuel Patrick Smith, ed. "The linking ring Vol 100 Issue 10", October 2020, p. 60
  45. ^ "2024 Class of Fellows of the AMS". American Mathematical Society. Retrieved 2023-11-09.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Doron_Levy&oldid=1228443984"